Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860739 | 0.80 | HRH3 (0.36) | HRH3KCNH2 | |
| SCHEMBL1781781 | 0.77 | EGLN1 (0.33) | HRH3 | |
| SCHEMBL19226648 | 0.76 | HRH3 (0.33) | HRH3 | |
| SCHEMBL19658447 | 0.75 | EGLN1 (0.36) | HRH3KCNH2 | |
| SCHEMBL24579155 | 0.75 | HRH3 (0.34) | HRH3KCNH2 | |
| SCHEMBL14453916 | 0.75 | HRH3 (0.35) | HRH3 | |
| SCHEMBL17886862 | 0.75 | HRH3 (0.33) | HRH3 | |
| SCHEMBL19652091 | 0.74 | DPP4 (0.39) | HRH3KCNH2 | |
| SCHEMBL4372402 | 0.74 | HRH3 (0.38) | HRH3KCNH2 | |
| SCHEMBL19083158 | 0.73 | HRH3 (0.33) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | claimed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | HRH3 3561/4885KCNH2 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.